Delta-sleep-inducing peptide reduces CRF-induced corticosterone release. — VialBase Research

Summary

Motivated by reports that delta-sleep-inducing peptide (DSIP) can affect several activities other than sleep, including reduction of stress, Graf and colleagues studied the effects of this nonapeptide on corticotropin releasing factor (CRF)-stimulated release of corticosterone in rats treated with chlorpromazine-morphine-pentobarbital. Significant reductions in corticosterone levels were observed after intravenous injection of DSIP at 5-30 micrograms/kg. Critically, no effect of DSIP was found on the corticosterone release elicited by injection of adrenocorticotropic hormone (ACTH). Because DSIP blunted the response to CRF but not the response to ACTH — which acts downstream at the adrenal — the authors concluded that DSIP attenuates the effects of CRF at the level of the pituitary. This is a rodent neuroendocrine experiment conducted in animals under a chlorpromazine-morphine-pentobarbital regimen, with corticosterone as the endpoint; it does not measure sleep, does not involve human subjects, and does not evaluate any behavioral or clinical stress outcome.

Key Findings

• Species: rats, treated with chlorpromazine-morphine-pentobarbital — a drug-conditioned preparation, not conscious free-living animals and not humans
• Intravenous DSIP at 5-30 micrograms/kg significantly reduced corticosterone levels in response to CRF stimulation
• DSIP produced no effect on corticosterone release elicited by ACTH injection, isolating the site of action upstream of the adrenal cortex
• The CRF-versus-ACTH dissociation supports the authors’ interpretation that DSIP attenuates CRF signaling at the level of the pituitary
• The study’s premise is explicitly that DSIP has activities beyond sleep, including reported stress reduction — the endpoints here are neuroendocrine, with no sleep measure taken

Relevance to DSIP

When vendors claim DSIP “lowers cortisol” or “reduces stress,” this 1985 rat paper is generally the study underneath the claim, and it is worth seeing plainly what it does and does not show. It shows that intravenous DSIP at 5-30 micrograms/kg significantly blunted CRF-stimulated corticosterone release in rats, and that it did not blunt ACTH-stimulated release — a clean dissociation pointing to a pituitary-level effect on CRF signaling. That is a legitimate and mechanistically interesting result. What it is not is human evidence: the subjects were rats, the animals were under a chlorpromazine-morphine-pentobarbital regimen, the hormone measured was corticosterone rather than the human cortisol, dosing was intravenous, and the experiment was a provoked CRF challenge rather than any measure of everyday stress. No sleep endpoint was assessed at all, so this study cannot be used to support DSIP as a sleep aid — it belongs to the separate line of work on DSIP’s non-sleep activities. Treat it as a forty-year-old preclinical mechanism paper that generates a hypothesis about HPA-axis modulation, and note that the corresponding human confirmation has not been produced.

Citation

Graf MV, Kastin AJ, Coy DH, et al. Delta-sleep-inducing peptide reduces CRF-induced corticosterone release. Neuroendocrinology. 1985;41(4):353-6. doi:10.1159/000124200.

See Also

• Parent compound: DSIP